Jens D Lundgren, Abdel G Babiker, Shweta Sharma, Birgit Grund, Andrew N Phillips, Gail Matthews, Virginia L Kan, Bitten Aagaard, Inka Abo, Beverly Alston, Alejandro Arenas-Pinto, Anchalee Avihingsanon, Sharlaa Badal-Faesen, Carlos Brites, Cate Carey, Jorge Casseb, Amanda Clarke, Simon Collins, Giulio Maria Corbelli, Sounkalo Dao, Eileen T Denning, Sean Emery, Nnakelu Eriobu, Eric Florence, Hansjakob Furrer, Gerd Fätkenheuer, Jan Gerstoft, Magnus Gisslén, Katharine Goodall, Keith Henry, Andrzej Horban, Jennifer Hoy, Fleur Hudson, Raja Iskandar Shah Raja Azwa, Eynat Kedem, Anthony Kelleher, Cissy Kityo, Karin Klingman, Alberto La Rosa, Nicolas Leturque, Alan R Lifson, Marcelo Losso, Joseph Lutaakome, Juan Sierra Madero, Patrick Mallon, Kamal Mansinho, Kamal Marhoum El Filali, Jean-Michel Molina, Daniel D Murray, Kumarasamy Nagalingeswaran, Silvia Nozza, Vidar Ormaasen, Roger Paredes, Luiz Carlos Peireira, Sandy Pillay, Mark N Polizzotto, Dorthe Raben, Armin Rieger, Adriana Sanchez, Mauro Schechter, Dalibor Sedlacek, Therese Staub, Giota Touloumi, Melissa Turner, Jose Valdez Madruga, Michael Vjecha, Marcelo Wolff, Robin Wood, Kai Zilmer, H Clifford Lane, James D Neaton
BACKGROUND: For people with HIV and CD4+ counts >500 cells/mm3 , early initiation of antiretroviral therapy (ART) reduces serious AIDS and serious non-AIDS (SNA) risk compared with deferral of treatment until CD4+ counts are <350 cells/mm3 . Whether excess risk of AIDS and SNA persists once ART is initiated for those who defer treatment is uncertain. METHODS: The Strategic Timing of AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults with CD4+ counts ...
March 2023: NEJM Evid